STXS
AMEXStereotaxis Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Website
News25/Ratings6
News · 26 weeks29+125%
2025-10-262026-04-19
Mix1590d
- SEC Filings7(47%)
- Earnings4(27%)
- Other3(20%)
- Insider1(7%)
Latest news
25 items- PRStereotaxis Announces First MAGiC Procedures in the United StatesST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™. MAGiC, Stereotaxis' proprietary robotically-navigated magnetic interventional cardiac ablation catheter, recently received Food & Drug Administration PMA approval. It is the first ablation catheter specifically approved to treat arrhythmia in patients with complex congenital heart disease. Dr. Nathan McConkey, Cardiac Electrophysiologist at Oregon Health & Science University, performed the first MAGiC procedure in the United States o
- PRStereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What: Stereotaxis first quarter 2026 financial results conference call When: Tuesday, May 12, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (Internati
- SECStereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Announces Definitive Agreement to Acquire RobocathST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions. This acquisition significantly strengthens Stereotaxis' position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions. "Robocath
- INSIDERSEC Form 4 filed by Peery Kimberly R.4 - Stereotaxis, Inc. (0001289340) (Issuer)
- PRStereotaxis Announces FDA Clearance and Launch of Synchrony SystemST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony's slim and stunning 55" 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab, offering an enhanced procedure experience with custom layouts, streamlined workflows, an intuitive user interface, and a decluttered environment. Synchrony digitizes the video streams with full
- SECAmendment: SEC Form 10-K/A filed by Stereotaxis Inc.10-K/A - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form DEFA14A filed by Stereotaxis Inc.DEFA14A - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form DEF 14A filed by Stereotaxis Inc.DEF 14A - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form EFFECT filed by Stereotaxis Inc.EFFECT - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form S-3 filed by Stereotaxis Inc.S-3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECStereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Reports 2025 Full Year Financial ResultsST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, Chairman and CEO. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, a
- PRStereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2025 financial results conference callWhen:Monday, March 9, 2026, at 4:30 p.m. ET (1:30 p.m. PT)Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 646-30
- PRKlinikum Fürth Establishes Leading Robotic Heart Arrhythmia ProgramST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany. Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of care for patients with arrhythmias. Physicians at Klinikum Fürth have successfully treated their first patients, with a wide range of arrhythmias, leveraging the advanced technology. "We are proud to
- PRStereotaxis Receives FDA Approval for MAGiC Ablation CatheterST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. "FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can support patients with complex and critical heart rhythm disorders, represents a major advance in robotic cardiac ablation technology, and provides a foundation for continued technological and cl
- INSIDERDirector Menawat Arun Swarup was granted 46,948 shares, increasing direct ownership by 5% to 992,457 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Benfer David was granted 46,948 shares, increasing direct ownership by 10% to 515,872 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Curet Myriam was granted 46,948 shares, increasing direct ownership by 14% to 392,058 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Shamir Nachum was granted 46,948 shares, increasing direct ownership by 53% to 136,224 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Levin Ross B was granted 46,948 shares, increasing direct ownership by 9% to 578,145 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Fischel Nathan was granted 46,948 shares, increasing direct ownership by 7% to 677,672 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- ANALYSTCitizens JMP initiated coverage on Stereotaxis with a new price targetCitizens JMP initiated coverage of Stereotaxis with a rating of Mkt Outperform and set a new price target of $4.00
- PRStereotaxis to Participate in Piper Sandler 37th Annual Healthcare ConferenceST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings. "This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the
- INSIDERDirector Isaac Paul J bought $66,600 worth of shares (30,000 units at $2.22), increasing direct ownership by 11% to 97,299 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)